June 7 Takeda Pharmaceutical Co Ltd:
* Takeda and Seattle Genetics announce Lancet publication of phase 3 alcanza clinical trial data of adcetris (brentuximab vedotin) for CD30-positive cutaneous t-cell lymphoma
* Takeda - takeda plans to begin to submit data from alcanza trial to regulatory agencies in its territories in 2017
* Takeda - Seattle Genetics plans to submit these data as part of a supplemental biologics license application to FDA in mid-2017 Source text for Eikon: Further company coverage:
WORLD NEWS SCHEDULE AT 1800 GMT/2 PM ET
Iraqi forces free hundreds of civilians in Mosul Old City battles as death toll mounts
CEO of Raytheon's Forcepoint eyes IPO -Boersen-Zeitung
FRANKFURT, June 24 U.S. missile maker Raytheon's cybersecurity unit could thrive were it to be listed separately, the head of the unit, Forcepoint, told German business daily Boersenzeitung in an interview published on Saturday.